Skip to main content
915 TLDR
Health
1 read

White House Denies Trump Received Experimental Obesity Drug Access

KTSMAshleigh Fields and The Hill
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KTSM

Read Original

AI Summary

The White House has dismissed rumors suggesting that former President Donald Trump was granted access to the experimental obesity drug retatrutide, produced by Eli Lilly, under a compassionate use program. This program typically allows patients with life-threatening conditions to access unapproved treatments. While the drug is not yet FDA-approved, it has been made available to select individuals under specific circumstances. The clarification from the White House highlights ongoing discussions around drug access and the implications of compassionate use policies.

health trump eli-lilly drug-access compassionate-use

People & Organizations

Donald TrumpEli Lilly

Related Articles